Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Phase 2
18–79
17 sites in AL, CA, MO +4
About this study
This Phase 2 study is focused on people with obesity. The primary outcome being measured is Incidence, severity and relationship of AEs/SAEs.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Incidence, severity and relationship of AEs/SAEs
Secondary: Absolute change in body weight from Baseline, Change in HbA1c from Baseline, PK parameters including but not limited to AUC, PK parameters including but not limited to Cmax, PK parameters including but not limited to Ctrough, Percent change in body weight from Baseline, TPK parameters including but not limited to Tmax
Endocrinology